Health Care International - ChemoCentryx Completes Enrollment Of PROTECT-1, A Phase II/III Clinical Trial Of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) In Crohn's Disease
ChemoCentryx, Inc., announced the completion of enrollment of 436 patients in the company's PROTECT-1 (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial), a Phase II/III clinical trial of Traficet-EN(TM) (CCX282-B) in patie
Comments